Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation.
Preclinical retinal neurodegeneration in a model of multiple sclerosis.
The "liberation procedure" for multiple sclerosis: sacrificing science at the altar of consumer demand.
Comment on the letter by Messori et al. (European Journal of Neurology 2013; 20: e131).
Multiplexing analysis of the polyspecific intrathecal immune response in multiple sclerosis.
Patient perceptions of multiple sclerosis and its treatment.
Disease-modifying drugs for multiple sclerosis and JC virus expression.
Sex ratio of multiple sclerosis in Canada: a longitudinal study.
Vision in a Phase 3 Trial of Natalizumab for Multiple Sclerosis: Relation to Disability and Quality of Life.
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.
The site of production of superoxide radical in mitochondrial Complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2.
MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis.
The King-Devick (K-D) test of rapid eye movements: A bedside correlate of disability and quality of life in MS.
Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica.
Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease.
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature.
European medicines agency's committee for medicinal products for human use issues positive opinion on marketing authorisation application for Fampyra
Laquinimod
[Epidemiology of multiple sclerosis in the Primosky Krai and Far East regions.]
Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis.
Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle.
Identification of endothelin 2 as an inflammatory factor that promotes central nervous system remyelination.
Quantitative MRI and Cerebrospinal Fluid Inflammatory Mediators in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis before and after Treatment with Immunomodulators: A Longitudinal Study.
Myotonic dystrophy type 2 and multiple sclerosis: Case report.

Pages